Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023

On September 27, 2023 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new clinical and pre-clinical data supporting its vision to extend the reach of cancer immunotherapies to new patient populations, in an oral presentation and four poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), taking place between 3-5 November 2023, San Diego, CA (Press release, Compugen, SEP 27, 2023, View Source [SID1234635476]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation details:

Abstract Title: Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response
Abstract number: 550
Presenter: Eran Ophir
Session: Cytokines in Cancer
Date: Friday, November 3, 2023
Time: 3:30 PM – 5:10 PM PDT

Poster presentation details:

Abstract Title: Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701 + nivolumab +/- BMS-986207 in patients with platinum resistant ovarian cancer
Abstract Number: 29
First Author: Gady Cojocaru
Date: Friday, November 3, 2023

Abstract Title: Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer
Abstract Number: 669
First Author: Stephanie Gaillard
Date: Friday, November 3, 2023

Abstract Title: Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response
Abstract number: 550
First Author: Assaf Menachem
Date: Saturday, November 4, 2023

Abstract Title: The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer
Abstract Number: 640
First Author: Ecaterina Dumbrava
Date: Saturday, November 4, 2023

Compugen’s abstracts will be available on the publications section of Compugen’s website, www.cgen.com